Acute On Chronic Liver Failure (ACLF) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Acute On Chronic Liver Failure (ACLF) - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Acute On Chronic Liver Failure
(ACLF) - Market Insights, Epidemiology, and Market Forecast-2030" report
delivers an in-depth understanding of the Acute On Chronic Liver Failure (ACLF)
, historical and forecasted epidemiology as well as the Acute On Chronic Liver
Failure (ACLF) market trends in the United States, EU5 (Germany, Spain, Italy,
France, and United Kingdom) and Japan.
·
Although a uniformly accepted definition for
epidemiological studies is lacking, ACLF is the most life-threatening
complication of cirrhosis. According to the US-national cohort study by Hernaez
et al., of 72,316 patients hospitalized for decompensated cirrhosis, 26.4%
(19,082) patients met the criteria of ACLF on admission. Of these, 12.8% had
one, 10.1% had two, and 3.5% had three or more organ failures, respectively.
·
Europe-based study analyzed the data from 1343
patients with cirrhosis and acute liver decompensation. The study reported a
prevalence of ACLF as 30.9% and was associated with a short-term (28-day)
mortality, i.e., 15 times higher than in cirrhotic patients without ACLF.
(Moreau et al.)
·
According to the study in Italy by Piano et al.,
it has been observed that among the 466 patients with cirrhosis, 118 patients
(25%) were reported to develop ACLF, in which the number of patients 57; 33;
and 28 belonged to grade-1, grade-2, and grade-3 ACLF, respectively. The study
concluded that outpatients with cirrhosis have a high risk of developing ACLF.
View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
·
The report covers the descriptive overview of
Acute On Chronic Liver Failure (ACLF) , explaining its causes, signs and
symptoms, pathophysiology, diagnosis and currently available therapies
·
Comprehensive insight has been provided into the
Acute On Chronic Liver Failure (ACLF) epidemiology and treatment in the 7MM
·
Additionally, an all-inclusive account of both
the current and emerging therapies for Acute On Chronic Liver Failure (ACLF)
are provided, along with the assessment of new therapies, which will have an
impact on the current treatment landscape
·
A detailed review of Acute On Chronic Liver
Failure (ACLF) market; historical and forecasted is included in the report,
covering drug outreach in the 7MM
·
The report provides an edge while developing business
strategies, by understanding trends shaping and driving the global Acute On
Chronic Liver Failure (ACLF) market
View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
The term ACLF
was first introduced in 1995 to describe a condition in which two “lesions” or
“insults” act simultaneously on the liver, one of which is chronic and the
other is acute. However, the universally accepted and used definition of ACLF
is still lacking. Therefore, several definitions have been developed by expert
groups from the American Association for the Study of Liver Diseases (AASLD),
European Association for the Study of the Liver (EASL), and Asian-Pacific
Association for the Study of the Liver (APASL).
According to AASLD and EASL working group ACLF is, “Acute
deterioration of pre-existing chronic liver disease usually related to a
precipitating event and associated with increased mortality at 3-months due to
multi-system organ failure”.On the other hand, the group of experts from APASL
define the ACLF as, “Acute liver injury manifesting as jaundice (serum
bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity of
<40%), complicated within 4 weeks by ascites and/or encephalopathy in a
patient previously diagnosed or undiagnosed chronic liver diseases.”
Organ failure is a major factor in the clinical course of
ACLF. Moreover, the presence of hepatic encephalopathy (HE) within 4 weeks is
part of the criteria for defining acute-on-chronic liver failure (ACLF).
It can be due to hepatotropic or non-hepatotropic
agents/causes. Major etiologic agents responsible for precipitating ACLF are
Hepatotropic viral infections, such as Hepatitis B virus, infection and
super-infection with HEV, etc., and Non-hepatotropic insults, like surgery,
trauma, and viral infections if producing direct hepatic insult could lead to
ACLF.
View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
·
Grifols Therapeutics
·
Promethera Biosciences
·
Umecrine Cognition
·
RHEACELL
·
And Many Others
·
Albutein 5% (also known as PE-A 5%)
·
HepaStem
·
GR3027
·
And Many Others
View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Key Questions
- What
was the Acute On Chronic Liver Failure (ACLF) market share (%)
distribution in 2017 and how it would look like in 2030?
- What
would be the Acute On Chronic Liver Failure (ACLF) total market size as
well as market size by therapies across the 7MM during the forecast period
(2017-2030)?
- What
are the key findings pertaining to the market across 7MM and which country
will have the largest Acute On Chronic Liver Failure (ACLF) market size
during the forecast period (2017-2030)?
- At
what CAGR, the Acute On Chronic Liver Failure (ACLF) market is expected to
grow in 7MM during the forecast period (2017-2030)?
- What
would be the Acute On Chronic Liver Failure (ACLF) market outlook across
the 7MM during the forecast period (2017-2030)?
- What
would be the Acute On Chronic Liver Failure (ACLF) market growth till
2030, and what will be the resultant market Size in the year 2030?
- How
would the market drivers, barriers and future opportunities affect the
market dynamics and subsequent analysis of the associated trends?
- What
is the disease risk, burden and unmet needs of the Acute On Chronic Liver
Failure (ACLF) ?
- What
is the historical Acute On Chronic Liver Failure (ACLF) patient pool in
seven major markets covering the United States, EU5 (Germany, Spain,
France, Italy, UK), and Japan?
- What
would be the forecasted patient pool of Acute On Chronic Liver Failure
(ACLF) in seven major markets covering the United States, EU5 (Germany,
Spain, France, Italy, UK), and Japan?
- What
will be the growth opportunities in the 7MM with respect to the patient
population pertaining to Acute On Chronic Liver Failure (ACLF) ?
- Out
of all 7MM countries, which country would have the highest prevalent
population of Acute On Chronic Liver Failure (ACLF) during the forecast
period (2017-2030)?
- At
what CAGR the population is expected to grow in 7MM during the forecast
period (2017-2030)?
View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Comments
Post a Comment